AstraZeneca PLC (AZN)vsUroGen Pharma Ltd (URGN)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
URGN
UroGen Pharma Ltd
$23.83
+2.10%
HEALTHCARE · Cap: $1.14B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 53402% more annual revenue ($58.74B vs $109.79M). AZN leads profitability with a 17.4% profit margin vs -139.8%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
URGN
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Intrinsic value data unavailable for URGN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Revenue surging 54.0% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -1481.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : URGN
The strongest argument for URGN centers on Revenue Growth, Debt/Equity. Revenue growth of 54.0% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : URGN
The primary concerns for URGN are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
AZN profiles as a value stock while URGN is a hypergrowth play — different risk/reward profiles.
URGN carries more volatility with a beta of 1.44 — expect wider price swings.
URGN is growing revenue faster at 54.0% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 28/100), backed by strong 17.4% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
UroGen Pharma Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
UroGen Pharma Ltd (URGN) is an innovative biotechnology company specializing in the development of specialized therapies for urological diseases, with a focus on urothelial carcinoma and bladder cancer. Leveraging its proprietary reverse thermal gel platform, UroGen enables targeted, sustained local drug delivery, thereby optimizing therapeutic efficacy while reducing systemic side effects. With a promising clinical pipeline addressing significant unmet medical needs in urology, UroGen is strategically poised to advance patient care and establish itself as a leader in the urological oncology space.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?